Colette Shortt, Regulatory Specialist and Visiting Professor University of Ulster, spoke about the regulatory framework for food supplements and Live Biotherapeutic products.
Hepatic encephalopathy is a debilitating and recurring condition that causes neuropsychiatric conditions and is a common complication of cirrhosis.
The findings of a new study suggest that infants acquire their gut virome from their diet and environment rather than from their mothers.
The findings of a new study reveal a microbe-immune axis that is disrupted in pregnant animals, suggesting potential therapeutic approaches for pregnancy-associated sepsis.
Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, spoke about how the research in gut-brain axes could pave the way to new microbiome based therapies in neurodegenerative diseases.
Industry
Sponsored by
Bio-Me launching an extensive qPCR solution for skin microbiome analysis.
Specific gut bacteria and/or metabolites could be responsible for the differential responses to weight management.
The findings of a new study suggest that a newborn’s lung immunity is influenced by the interplay between maternal γδ T cells, the gut microbiota and microbial-derived SCFAs.
Oliver Worsley: ‘The collaboration will give us the opportunity to further understand how molecular changes on the skin may translate to skin and human health’.
Tim Sharpington, Chief Executive Officer at Microbiotica, talked about how the microbiome field should navigate through a difficult financing horizon.
